$AMRN On Thursday evening, hours before the Hikma announcement, Amarin had said it would support a trial of Vascepa as a Covid-19 treatment. The company said that because Vascepa can lower cardiovascular risk in certain patients—and because patients at high risk of cardiovascular disease are at higher risk of dying from Covid-19—it was believed that Vascepa could help Covid-19 patients.
  • 4